CA2280873C - The use of latency associated peptide in wound healing - Google Patents

The use of latency associated peptide in wound healing Download PDF

Info

Publication number
CA2280873C
CA2280873C CA2280873A CA2280873A CA2280873C CA 2280873 C CA2280873 C CA 2280873C CA 2280873 A CA2280873 A CA 2280873A CA 2280873 A CA2280873 A CA 2280873A CA 2280873 C CA2280873 C CA 2280873C
Authority
CA
Canada
Prior art keywords
wound
pharmaceutical composition
latency associated
fragment
associated peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2280873A
Other languages
English (en)
French (fr)
Other versions
CA2280873A1 (en
Inventor
Mark William James Ferguson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Renovo Ltd
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovo Ltd filed Critical Renovo Ltd
Publication of CA2280873A1 publication Critical patent/CA2280873A1/en
Application granted granted Critical
Publication of CA2280873C publication Critical patent/CA2280873C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
CA2280873A 1997-02-13 1998-02-13 The use of latency associated peptide in wound healing Expired - Fee Related CA2280873C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9702943.3A GB9702943D0 (en) 1997-02-13 1997-02-13 Wound healing
GB9702943.3 1997-02-13
PCT/GB1998/000316 WO1998035695A1 (en) 1997-02-13 1998-02-13 Wound healing

Publications (2)

Publication Number Publication Date
CA2280873A1 CA2280873A1 (en) 1998-08-20
CA2280873C true CA2280873C (en) 2010-04-06

Family

ID=10807557

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2280873A Expired - Fee Related CA2280873C (en) 1997-02-13 1998-02-13 The use of latency associated peptide in wound healing

Country Status (12)

Country Link
US (1) US6319907B1 (enExample)
EP (1) EP1009425B1 (enExample)
JP (1) JP4307561B2 (enExample)
AT (1) ATE223228T1 (enExample)
AU (1) AU728851B2 (enExample)
CA (1) CA2280873C (enExample)
DE (1) DE69807710T2 (enExample)
DK (1) DK1009425T3 (enExample)
ES (1) ES2181165T3 (enExample)
GB (1) GB9702943D0 (enExample)
PT (1) PT1009425E (enExample)
WO (1) WO1998035695A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756060B1 (en) * 1996-09-19 2004-06-29 Usbiomaterials Corp. Anti-inflammatory and antimicrobial uses for bioactive glass compositions
US6767891B2 (en) * 2000-06-14 2004-07-27 Chanda Zaveri Peptides with wound healing activity
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
US20030148924A1 (en) * 2002-07-09 2003-08-07 Tamar Tennenbaum Methods and pharmaceutical compositions of healing wounds
US20040037828A1 (en) * 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
ATE429925T1 (de) * 2000-07-31 2009-05-15 Univ Bar Ilan Methoden und pharmazeutische zusammensetzungen zur wundheilung
US20100129332A1 (en) * 2000-07-31 2010-05-27 Tamar Tennenbaum Methods and pharmaceutical compositions for healing wounds
US20050164909A1 (en) * 2003-07-16 2005-07-28 The Ohio State University Research Foundation Methods and reagents for treating inflammation and fibrosis
WO2005013885A2 (en) * 2003-08-07 2005-02-17 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
WO2007026356A2 (en) * 2005-08-29 2007-03-08 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
KR20150072458A (ko) 2006-11-15 2015-06-29 코다 테라퓨틱스, 인크. 상처 치유를 위한 개선 방법 및 조성물
EP2653166A3 (en) * 2007-07-30 2014-08-27 Healor Ltd. Pharmaceutical composition and related methods
CN101855235B (zh) * 2007-10-29 2013-04-24 赫里克斯生物医疗公司 保护性皮肤护理四肽
CA2710375A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of orthopedic conditions
EP2252690A2 (en) * 2007-12-21 2010-11-24 Coda Therapeutics, Inc. Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
EP2234656A2 (en) 2007-12-21 2010-10-06 Coda Therapeutics, Inc. Improved medical devices
US20100172217A1 (en) * 2009-01-08 2010-07-08 Von Bezold Ernst System of Methods and Apparati for Handling and Modifying Information Energy and Matter by Formative Resonance
ES2601827T3 (es) * 2009-02-24 2017-02-16 Arava Bio-Tech Ltd. Agentes antagonistas de visfatina para el tratamiento del acné y de otras afecciones
WO2011083483A2 (en) 2010-01-11 2011-07-14 Healor Ltd. Method for treatment of inflammatory disease and disorder
US9387183B2 (en) 2011-12-28 2016-07-12 Kuwait University Method of treating diabetes-related impaired wound healing
JP6683686B2 (ja) 2014-08-22 2020-04-22 オークランド ユニサービシーズ リミティド チャネル調節剤
US10232009B1 (en) * 2017-09-29 2019-03-19 Pro Sunfun Biotech Research And Development Co., Ltd. Peptide for promoting wound healing, its composition and method of using the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2068204C (en) * 1989-11-22 2002-02-12 Arthur Levinson Latency associated peptides and uses therefor
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
AU5587094A (en) * 1992-10-26 1994-05-24 Kirin Brewery Company, Limited Method for producing large latent transforming growth factor-beta complexes and large latency associated peptide
US6074840A (en) * 1994-02-18 2000-06-13 The Regents Of The University Of Michigan Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
AU710153B2 (en) * 1994-03-29 1999-09-16 Renovo Limited Wound healing

Also Published As

Publication number Publication date
ATE223228T1 (de) 2002-09-15
AU728851B2 (en) 2001-01-18
US6319907B1 (en) 2001-11-20
AU5995398A (en) 1998-09-08
DE69807710T2 (de) 2003-06-05
DE69807710D1 (de) 2002-10-10
DK1009425T3 (da) 2002-10-14
PT1009425E (pt) 2002-11-29
CA2280873A1 (en) 1998-08-20
HK1025504A1 (en) 2000-11-17
EP1009425A1 (en) 2000-06-21
JP2001511797A (ja) 2001-08-14
JP4307561B2 (ja) 2009-08-05
GB9702943D0 (en) 1997-04-02
WO1998035695A1 (en) 1998-08-20
EP1009425B1 (en) 2002-09-04
ES2181165T3 (es) 2003-02-16

Similar Documents

Publication Publication Date Title
CA2280873C (en) The use of latency associated peptide in wound healing
CA2709398C (en) Use of stromal cell-derived factor 1 for promoting wound healing
EP0855916B1 (en) Pharmaceutical composition containing an activin stimulator
JP2005290009A (ja) 線維障害の創傷治療処置
CN102056619A (zh) 产生和使用原胶原的方法
WO1998036061A2 (en) Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity
AU2006268091B2 (en) Promotion of epithelial regeneration
US7282208B2 (en) Method for stimulating wound healing
EP0941108B1 (en) Wound healing and treatment of fibrosis
Sheardown et al. Continuous epidermal growth factor delivery in corneal epithelial wound healing.
EP2968436A2 (en) The use of sdf-1 to mitigate scar formation
HK1025504B (en) Use of latency associated peptide for the manufacture of a medicament for increasing wound healing
GB2324960A (en) Delivery of naked DNA for wound healing
HK1025732B (en) Wound healing and treatment of fibrosis

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130213